Cooper Companies (NYSE:COO)‘s stock had its “buy” rating reaffirmed by Raymond James Financial in a report released on Monday. They presently have a $265.00 price target on the medical device company’s stock. Raymond James Financial’s price target indicates a potential upside of 15.35% from the company’s current price.

Other research analysts have also issued reports about the stock. Robert W. Baird reiterated a “buy” rating and set a $267.00 price target (up from $251.00) on shares of Cooper Companies in a research note on Sunday, September 3rd. BMO Capital Markets reiterated a “buy” rating and set a $272.00 price target on shares of Cooper Companies in a research note on Friday, September 1st. Cleveland Research reiterated a “buy” rating on shares of Cooper Companies in a research note on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $277.00 price target on the stock in a research note on Tuesday, August 22nd. Finally, Jefferies Group set a $250.00 price target on shares of Cooper Companies and gave the stock a “buy” rating in a research note on Thursday, August 17th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Cooper Companies presently has a consensus rating of “Buy” and a consensus target price of $260.70.

Shares of Cooper Companies (NYSE COO) traded down $8.36 during trading on Monday, hitting $229.74. 493,900 shares of the stock were exchanged, compared to its average volume of 420,483. Cooper Companies has a twelve month low of $161.52 and a twelve month high of $256.39. The company has a current ratio of 2.51, a quick ratio of 1.29 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $11,250.00, a price-to-earnings ratio of 25.47, a price-to-earnings-growth ratio of 2.02 and a beta of 0.54.

In other Cooper Companies news, Director Gary S. Petersmeyer sold 3,977 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $244.94, for a total transaction of $974,126.38. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. AXA grew its position in shares of Cooper Companies by 3.0% in the third quarter. AXA now owns 193,969 shares of the medical device company’s stock valued at $45,992,000 after purchasing an additional 5,725 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Cooper Companies by 354.8% in the third quarter. GSA Capital Partners LLP now owns 6,449 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 5,031 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Cooper Companies by 11.4% in the third quarter. California Public Employees Retirement System now owns 120,582 shares of the medical device company’s stock valued at $28,591,000 after purchasing an additional 12,382 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of Cooper Companies by 3.5% in the third quarter. Janney Montgomery Scott LLC now owns 10,817 shares of the medical device company’s stock valued at $2,565,000 after purchasing an additional 363 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Cooper Companies in the third quarter valued at approximately $2,161,000. Institutional investors own 96.79% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/05/raymond-james-financial-reaffirms-buy-rating-for-cooper-companies-coo.html.

About Cooper Companies

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.